Paradigm’s (ASX:PAR) immediate commercial focus is the development of pentosan polysulfate sodium (PPS) for the treatment of osteoarthritis (OA). This is a global unmet need and we have advanced to phase 3 trials in the space. Addressing all aspects of the disease: inflammation, pain, and regeneration, the non-opioid PPS has genuine disease-modifying potential.
Company Details
- Employees
- 25
- Founded
- -
- Address
- 500 Collins, L2 517 Flinders Lane,australia
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- HQ
- Melbourne, Victoria
Paradigm Biopharmaceuticals Questions
Paradigm Biopharmaceuticals's website is http://www.paradigmbiopharma.com/
Paradigm Biopharmaceuticals's LinkedIn profile is https://au.linkedin.com/company/paradigm-biopharmaceuticals
Paradigm Biopharmaceuticals has
25 employees.
View email and phone details for 25
employees at Paradigm Biopharmaceuticals.
Paradigm Biopharmaceuticals's industry is
Pharmaceutical Manufacturing
Paradigm Biopharmaceuticals's top competitors are
Dimerix Limited,
Prescient Therapeutics,
Oakrum Pharma, Llc,
Imugene Limited,
Vaxxas,
Orthocell Ltd,
Clarity Pharmaceuticals,
Chimeric Therapeutics,
Cynata Therapeutics,
Advanced Clinical.
Paradigm Biopharmaceuticals's categories are Pharmaceutical Manufacturing
Paradigm Biopharmaceuticals's founding year is 2014
